MedTrace Logo

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

NCT01614912 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 284

Last updated 2022-04-12

Study results available
· View outcomes & findings →

Summary

The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.

Conditions

Interventions

DRUG

SM-13496

40 or 80 mg once daily orally

Sponsors & Collaborators

  • Sumitomo Pharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Japan
  • Malaysia
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01614912 on ClinicalTrials.gov